Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-centered，Randomized，Double-blind，Placebo-controlled Study to Evaluate the Efficacy and Safety of SHR-1703 in Eosinophilic Asthma

NCT06653322 is registered in ClinicalTrials.gov with Guangdong Hengrui Pharmaceutical Co., Ltd as lead sponsor.

NCT NCT06653322
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06653322 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-centered，Randomized，Double-blind，Placebo-controlled Study to Evaluate the Efficacy and Safety of SHR-1703 in Eosinophilic Asthma
Lead sponsor
Guangdong Hengrui Pharmaceutical Co., Ltd
Phase
Phase 3
Overall status
Active, not recruiting
Start date
November 21, 2024
Completion date
December 31, 2027
Enrollment
401 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

asthma with eosinophilic phenotype